Related Content
Download content relating to this event and topic.
The 16th Annual Vaccine World Summit unites global stakeholders to advance vaccine development and distribution, emphasizing India's production capacity and developing nations' access.

The 16th Annual Vaccine World Summit brings together leading stakeholders from across the vaccine ecosystem to strategize, collaborate, and address key challenges in vaccine development, manufacturing, and distribution. With India playing a pivotal role in global vaccine production, the summit places a special emphasis on the needs of developing nations. It serves as a platform to foster partnerships, exchange knowledge, and drive innovation aimed at improving vaccine access, affordability, and equity. By leveraging India’s strengths and aligning with the priorities of underserved regions, the summit aspires to advance universal immunization and strengthen public health outcomes worldwide.


View the Key Themes for
Vaccines World Summit 2026
Register today to secure your ticket.
Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.


Mr. Prashant Chawla is a seasoned Bioprocess Manager with over 20 years of progressive experience in drug substance manufacturing, process engineering, validation, and regulatory compliance. His career spans prestigious Indian and multinational organizations, including Hyde Engineering & Consulting, Serum Institute of India, and currently, Biological E Ltd.
With a deep-rooted expertise in vaccine bulk antigen manufacturing, Mr. Chawla has led end-to-end operations encompassing scale-up, technology transfer, and cGMP compliance for critical vaccines such as Diphtheria, Hib Conjugate Vaccine, and Typhoid Vi Polysaccharide. He has played a pivotal role in the successful manufacturing of Typhoid O2 Polysaccharide, CRM197, and CORBEVAX (COVID-19 Vaccine), steering cross-functional teams to deliver operational excellence.
Mr. Chawla has overseen technology transfers for both bacterial and recombinant antigen production, consistently optimizing production timelines and resources while ensuring alignment with stringent global regulatory frameworks, including USFDA, EU, WHO, and ANVISA standards.
In addition to his technical acumen, Mr. Chawla holds certifications in Lean Six Sigma Green Belt (LSSGB), and has pursued professional development in Managerial Economics and Operations Management.
He holds a Master’s degree in Bioprocess Engineering from ICT and a Bachelor’s degree in Chemical Engineering, complemented by multiple cGMP certifications and regulatory training credentials.


Rajinder as CEO-DCVMN International is responsible for providing leadership, shaping strategic vision, governance and overall operational excellence of DCVMN. Rajinder is committee delegate on GAVI-PPC, a member of GAVI’s Vaccine Investment Strategy (VIS) Steering Committee 2024, a permanent member of CEPI’s Joint Coordination Group (JCG), 2023-24 and a member of PAVMs Talent Development WS as well as Strategic Advisory Board (SAB) of the Regional Vaccine Manufacturing Collaborative (RVMC).
In response to un-precedented challenge posed by COVID-19, Rajinder has actively participated in global strategic initiatives alongside COVAX partners-WHO, GAVI, CEPI, UNICEF and various other international organizations and industry associations.
Rajinder has contributed as a member of several advisory expert groups including COVAX Manufacturing & Supply Chain Task Force Leadership Team, G-20 Health Working Group under Indonesia and India presidency and Market Design and Demand Intelligence pillar of PAVM. He is on the Governing Board of Life Sciences Skill Development Council (LSSSDC).
With over 25 years of top management experience in the industry, Rajinder has served on the Board of Directors of the Indian subsidiary of Sanofi Pasteur and held the position of CEO-Panacea Biotec. Rajinder has served earlier as Member-GAVI-PPC as well as Vice-President, DCVMN Executive Committee from 2014-16.


Dr. Kapil Maithal is currently working as President – Vaccines and Diagnostics at Zydus Lifesciences, India. He has over 25years of experience in the field of Vaccines, Biologicals and Diagnostics Research, Development and Manufacturing.
He did his doctorate in biochemistry from University of Delhi, followed by post-doctoral research in structural biology fromIndian Institute of Sciences, Bangalore. Subsequently, he joined as a faculty at University of Delhi in Biomedical researchbefore moving to industry, where over the years he has led the development of numerous viral, bacterial, toxoid,polysaccharide, conjugate and protein subunit vaccines for human and veterinary use. Recently, he also led the research &development of World’s First Licensed human DNA Vaccine, ZyCoV-D® against COVID-19.
He also has interest in global public health and has served as a member of Independent Review Committee of GAVIAlliance, Geneva, Expert Working Group of “Vaccines & Immunosera for human use” of Indian PharmacopoeiaCommission and Technical Expert Committee of BIRAC, Govt. of India. He has also been on the recruitment panel ofNISCAIR, CSIR; Gujarat Biotechnology University and advisory board for BIRAC -GMP Project of CSIR-IMTECH and School ofBiotechnology, Jawaharlal Nehru University, Delhi.
Dr. Maithal is also a fellow of Royal Society of Chemistry, UK and Royal Society of Biology, UK. He has number of patentsand international publications in peer reviewed journals to his credit and is also a reviewer to number of peer reviewedjournals including Vaccine, NPJ Vaccines, International Journal of Medicine and Medical sciences, PLOS ONE etc.


Syed S Ahmed is the Director & CEO of Techinvention Lifecare Limited, India (A Forbes India 200 listed company in 2024) which is into Vaccines & IVD: Development and Manufacturing with focus on the Global South. He also serves as Vice President & Board Member of Emerging Biopharmaceutical Manufacturers Network https://www.ebpmn-international.org/. A Not-For-Profit Association of 10 leading Biopharmaceutical manufacturers from Emerging markets. With TechInvention : Syed has over 15 Patents filed in the field of vaccines, diagnostics and novel biotherapeutics & 5+Publications in High Impact factor Journals. He has led challenging Vaccine initiatives and Projects to Success across Latam, Africa & Asia with unconventional strategies which forms the essence of his today's presentation.






Dr. Nupur Sengupta, Senior General Manager at Biological E Ltd. is a dynamic leader in the field of vaccines and bio-pharmaceuticals, specifically an Expert in Bacterial Vaccines, is driven by her passion for advancing global health.
With a PhD in Structural Biology, an MBA, and over 15 years of industry experience, she blends deep scientific expertise with strategic business acumen to build impactful collaborations that bring life-saving vaccines and drugs to communities worldwide. Currently at Biological E Ltd. in the Global Alliance and Partnership Management for Vaccines, Nupur plays a pivotal role in forging partnerships, steering innovative projects, and ensuring that critical vaccines reach those who need them most.
Beyond her professional journey, she is also a classical dancer, a curious traveller, and a nature photographer - interests that fuel her creativity and well-rounded outlook on life.


Dr. Arani Chatterjee is currently President (CRO) at Cadila Pharmaceuticals, which is one of the oldest and the largest privately held pharmaceutical company of India. In this role, Dr. Chatterjee is responsible for Pre-Clinical and Clinical Research including BA/BE studies, bioanalytical assays and clinical trials. He also oversees Pharmacovigilance at Cadila Pharmaceuticals.
Prior to joining Cadila pharmaceuticals, he served at Aurobindo Pharma, Biological E, Panacea Biotec and Dr. Reddy’s Research Foundation since 1998. During his tenure he made significant contributions to the clinical development of New Chemical Entities, vaccines, novel drug delivery products, complex generics and biologics.
Dr. Arani Chatterjee earned his medical degree from Christian Medical College, Vellore and postgraduate degree from National Institute of Mental Health and Neuro Sciences, Bangalore, India. He is also an alumnus of Indian Institute of Management, Indore, India.
He has served as a WHO Adviser for the Global Polio Eradication Initiative and was a member of the drafting group for WHO Guidelines on clinical evaluation of vaccines: regulatory expectations. He was a member of several Brighton Collaboration groups for vaccine safety. He has participated in WHO Strategic Advisory Group of Experts on Immunization and Global Vaccine Safety Initiative meetings, Asia Pacific Dengue Prevention Board Meeting under the Pediatric Dengue Vaccine Initiative of International Vaccine Institute and Pneumococcal Vaccines meetings at UNICEF. He has also participated in in-person pre-IND meetings with USFDA, scientific advice meetings with BfArM (Germany), ANVISA (Brazil), Medsafe (New Zealand), ALIMS (Serbia) and NORCB (Egypt) as well as expert group meetings on Indian GCP guidelines and National Technology Advisory Group on Immunisation meetings.
Dr. Chatterjee serves as a reviewer for the journal ‘Vaccine’ and has 24 peer-reviewed international research publications and 4 book chapters to his credit. He was awarded the prestigious 2012 Charles C. Shepard Award from CDC, Atlanta in 2012.


Peter Tygesen is Business Development Director, Vaccine Adjuvants at SPI Pharma. An organic chemist by training, he has spent more than 30 years in the pharmaceutical industry, with over a decade focused on vaccine adjuvant innovation. Before joining SPI Pharma in May 2025, Peter led Brenntag Biosector (later Croda Denmark), a global supplier of aluminium and saponin-based adjuvants, and then served as Managing Director for Vaccine Adjuvant Systems at Croda Pharma. Across these roles he has helped shape the modern adjuvant landscape, supporting the development of safe, effective and more accessible vaccines worldwide.
Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.
Apply to SpeakChoose a plan that fits your role, company, and industry.
Early Bird Rate : SGD 1,495
(Valid until 29th August 2025)
Registration Open Rate : SGD 1,695
(Valid until 24th October 2025)
Standard Rate : SGD 1,895
(Valid until 26th December 2025)
Final Call Rate : SGD 2,095
(Valid until 6th February 2026)
Applicable to company profiles (headquartered within the APAC region):
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Early Bird Rate : SGD 1,995
(Valid until 29th August 2025)
Registration Open Rate : SGD 2,195
(Valid until 24th October 2025)
Standard Rate : SGD 2,395
(Valid until 26th December 2025)
Final Call Rate : SGD 2,595
(Valid until 6th February 2026)
Applicable to company profiles (headquartered outside of the APAC region):
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
Early Bird Rate : SGD 2,995
(Valid until 29th August 2025)
Registration Open Rate : SGD 3,195
(Valid until 24th October 2025)
Standard Rate : SGD 3,395
(Valid until 26th December 2025)
Final Call Rate : SGD 3,595
(Valid until 6th February 2026)
Applicable to company profiles:
Job Profiles: Business Development, Marketing, and Sales
Be the first in line! Register your interest now to get exclusive access to Super Early-Bird tickets - the lowest prices available - before they go live.
Contact the IMAPAC to learn about our sponsorship process, rates and more.
Visit the event page to view more content.
Download content relating to this event and topic.
Visit the event page to view more content.
Visit the awards page to view more content.
To stay informed about event updates, including date, venue, and agenda, please subscribe to our our official social media channels for real-time updates and announcements.
The conference will provide a comprehensive learning experience covering various aspects of the dynamic biopharmaceutical industry, ensuring attendees gain valuable insights and knowledge.
We are committed to ensuring the safety and well-being of all attendees. We will implement rigorous safety measures in line with local health guidelines and regulations. Specific safety measures will be communicated closer to the event date to ensure they align with the most up-to-date health recommendations. Rest assured, your safety is our priority.
We welcome presentation submissions. If you’re interested in speaking at the event, please visit this page on our website for submission guidelines and deadlines.
Our event is designed to cater to a wide range of professionals within the biopharmaceutical industry, including researchers, scientists, executives, regulatory experts, and professionals involved in drug development and manufacturing.
Participants can expect to gain insights from industry experts, network with peers, and stay up-to-date with the latest trends and innovations in biopharmaceuticals
Yes, we have networking sessions, workshops, and social events scheduled throughout the event to facilitate connections and collaborations among attendees.
Yes, we offer sponsorship and exhibition opportunities for businesses and organizations. Please visit our this page on our website for more information.
To register for the event, you'll find multiple "register" buttons on this page to get started. You’ll find detailed instructions and options for registration, including pricing and deadlines.
Don't miss out on unique networking, speaking and sponsorship opportunities.